TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38329732
Drug: Paclitaxel treatment
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel treatment in breast cancer cohorts
Study: 38329737
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy in combination with radiotherapy (IC-RT) group
Study: 38329737
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy combined with chemoradiotherapy (IC-CCRT) group
Study: 38330285
Drug: Apitegromab 20
Normalized name: Apitegromab
DrugBank: Apitegromab (DB16096)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apitegromab 20 mg/kg alone or in combination with nusinersen (Cohort 1)
Study: 38330285
Drug: Apitegromab 20
Normalized name: Apitegromab
DrugBank: Apitegromab (DB16096)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apitegromab 20 mg/kg combined with nusinersen (Cohort 2)
Study: 38330285
Drug: Apitegromab 2
Normalized name: Apitegromab
DrugBank: Apitegromab (DB16096)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apitegromab 2 mg/kg combined with nusinersen (Cohort 3)
Study: 38330285
Drug: Apitegromab 20
Normalized name: Apitegromab
DrugBank: Apitegromab (DB16096)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apitegromab 20 mg/kg combined with nusinersen (Cohort 3)
Study: 38330357
Drug: rCSP/GLA-LSQ 10 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: rCSP/GLA-LSQ 10 µg × 3
Study: 38330357
Drug: rCSP/GLA-LSQ 30 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: rCSP/GLA-LSQ 30 µg × 3
Study: 38330357
Drug: rCSP/GLA-LSQ 60 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: rCSP/GLA-LSQ 60 µg × 3
Study: 38330357
Drug: rCSP/GLA-LSQ 60 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: rCSP/GLA-LSQ 60 µg × 2
Study: 38330357
Drug: rCSP 30 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: rCSP 30 µg alone × 3
Study: 38330377
Drug: RKP00156 vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: RKP00156 vaginal tablet (25 mg dose)
Study: 38330377
Drug: RKP00156 vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: RKP00156 vaginal tablet (10 mg or 50 mg doses)
Study: 38330377
Drug: RKP00156 vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: RKP00156 vaginal tablet
Study: 38330380
Drug: Surgical debulking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical debulking of bulky or multiple lymph nodes before concurrent chemoradiation therapy (CCRT)
Study: 38330409
Drug: Daily glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily glucose monitoring
Study: 38330942
Drug: ADG106 (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADG106 (5.0 mg/kg dose level)
Study: 38330942
Drug: ADG106 (10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADG106 (10.0 mg/kg dose level)
Study: 38330975
Drug: Onradivir 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onradivir 200 mg twice per day
Study: 38330975
Drug: Onradivir 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onradivir 400 mg twice per day
Study: 38330975
Drug: Onradivir 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onradivir 600 mg once per day
Study: 38330987
Drug: Survodutide 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survodutide 0.6 mg
Study: 38847460
Drug: Survodutide 2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survodutide 2.4 mg
Study: 38330987
Drug: Survodutide 3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survodutide 3.6 mg
Study: 38847460
Drug: Survodutide 4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survodutide 4.8 mg
Study: 38331348
Drug: L-carnitine syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine syrup (100 mg/kg/d) for 15 days
Study: 38332651
Drug: Pre-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment
Study: 38332651
Drug: Fixed-dose hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose hydroxyurea
Study: 38332651
Drug: Dose escalation
Normalized name: PALFORZIA Initial Dose Escalation KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation hydroxyurea
Study: 38332984
Drug: Transcranial direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial direct current stimulation (tDCS) for 20 minutes at 2 mA for 10 daily sessions
Study: 38333020
Drug: Callergin (iota-carrageenan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Callergin (iota-carrageenan nasal spray)
Study: 38333967
Drug: ACLR+LEAP augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACLR+LEAP augmentation
Study: 38334147
Drug: Oral methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate (5 mg/m²)
Study: 38334147
Drug: Methotrexate plus
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate plus intra-articular glucocorticoid (IAGC) therapy
Study: 38334413
Drug: Topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine 0.1% solution
Study: 38334470
Drug: Low-dose positron
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose positron emission mammography (PEM) with up to 185 MBq of fluorine 18-labeled fluorodeoxyglucose
Study: 38335023
Drug: Wellinks intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Wellinks intervention with remote health coaching, pulmonary rehabilitation, and group education; 6 coaching sessions in the first 12 weeks, followed by reduced frequency or discontinuation in the second 12 weeks.
Study: 38335032
Drug: brepocitinib 45
Normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: brepocitinib 45 mg
Study: 38335032
Drug: zimlovisertib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: zimlovisertib 400 mg
Study: 38335032
Drug: ropsacitinib 400
Normalized name: Ropsacitinib
DrugBank: Ropsacitinib (DB18709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropsacitinib 400 mg
Study: 38335386
Drug: Integrative Korean
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative Korean medicine treatment (herbal medicine, acupuncture, pharmacopuncture, bee venom pharmacopuncture, Chuna therapy, KM physiotherapy)
Study: 38335474
Drug: Evobrutinib 75
Normalized name: Evobrutinib
DrugBank: Evobrutinib (DB15170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evobrutinib 75 mg BID
Study: 38335474
Drug: Evobrutinib 25
Normalized name: Evobrutinib
DrugBank: Evobrutinib (DB15170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evobrutinib 25 mg QD
Study: 38335474
Drug: Evobrutinib 75
Normalized name: Evobrutinib
DrugBank: Evobrutinib (DB15170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evobrutinib 75 mg QD
Study: 38335474
Drug: Placebo (switched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (switched to evobrutinib 25 mg QD after week 24)
Study: 38335474
Drug: Open-label dimethyl
Normalized name: Dimethyl sulfone
DrugBank: Dimethyl sulfone (DB14090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label dimethyl fumarate (DMF) 240 mg BID
Study: 38335499
Drug: Vamorolone 6
Normalized name: Vamorolone
DrugBank: Vamorolone (DB15114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vamorolone 6 mg/kg/d
Study: 38335499
Drug: Vamorolone 2
Normalized name: Vamorolone
DrugBank: Vamorolone (DB15114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vamorolone 2 mg/kg/d
Study: 38335850
Drug: Palliative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Palliative radiotherapy (electron beam and photon beam therapies)
Study: 38335978
Drug: Eltrombopag (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag (150 mg, 100 mg for Asian patients) and cyclosporin A (10 mg/kg per day)
Study: 38336731
Drug: PrEPare for
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: PrEPare for Work Stage 2 intervention (1-on-1 skills training, problem-solving, and motivational interviewing adherence counseling and personalized, daily text message reminders)
Study: 38336815
Drug: VagiBIOM suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: VagiBIOM suppository
Study: 38339248
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus 5-Azacitidine (3 mg/kg/dose)
Study: 38340111
Drug: Esketamine treatment
Normalized name: esketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine treatment
Study: 38340349
Drug: Immediate chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate chemotherapy (within 90 days after radium-223)
Study: 38340349
Drug: Delayed chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed chemotherapy (more than 90 days after radium-223)
Study: 38340349
Drug: Overall (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall (both immediate and delayed chemotherapy)
Study: 38340677
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine 133 mg
Study: 38340677
Drug: Bupivacaine hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine hydrochloride 50 mg
Study: 38340723
Drug: Higher circulating
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher circulating MCPyV-specific CD8 T cell frequency before anti-PD-1 treatment
Study: 38341525
Drug: Transversus thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transversus thoracic muscle plane block (TTMPB) with 20 ml of 0.25% bupivacaine on each side
Study: 38341525
Drug: Pecto-intercostal fascial
Normalized name: Rompe Pecho
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pecto-intercostal fascial block (PIFB) with 20 ml of 0.25% bupivacaine on each side
Study: 38342115
Drug: 9 mg
Normalized name: fiber 469 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg oral enobosarm daily
Study: 38342115
Drug: 18 mg
Normalized name: niacin 18 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 mg oral enobosarm daily
Study: 38342430
Drug: Neoadjuvant immunochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant immunochemotherapy with adjuvant therapy
Study: 38342441
Drug: Prednisone 40
Normalized name: prednisone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 40 mg orally for 30 days
Study: 38342441
Drug: A+Z (anakinra
Approvals — FDA: no, EMA: no, PMDA: no
Description: A+Z (anakinra 100 mg subcutaneously for 14 days plus zinc sulfate 220 mg orally for 90 days)
Study: 38342735
Drug: Behavioral Activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Activation (BA) intervention consisting of 10 weekly sessions including psychoeducation about depression, life areas and values assessment, activity scheduling, and self-monitoring of satisfaction and mood.
Study: 38342735
Drug: Supportive Psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive Psychotherapy (SP) as a standard of care control intervention consisting of 10 weekly sessions of reassurance, guidance, encouragement, and support.
Study: 38343807
Drug: High-dose bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose bolus of cholecalciferol (vitamin D)
Study: 38344130
Drug: Scaling up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling up direct-acting antiviral (DAA) treatment in prisons by 44% for 10 years (2021-2030)
Study: 38344130
Drug: Scaling up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling up HCV treatment excluding DAA pharmaceutical costs
Study: 38344130
Drug: Scaling up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling up HCV testing and treatment in prisons
Study: 38344130
Drug: Status quo
Normalized name: Statuss Green Reformulated Jan 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Status quo scenario (baseline levels of HCV treatment)
Study: 38344178
Drug: 15 mg-tolvaptan
Normalized name: tolvaptan 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg-tolvaptan administered orally for 7 consecutive days
Study: 38344232
Drug: Art-producing activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Art-producing activities in a hybrid format (in-person and online) for 3 months on a weekly basis
Study: 38344820
Drug: Insulin glargine,
Normalized name: insulin glargine, human recombin. analog
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin glargine, glimepiride, sitagliptin
Study: 38344891
Drug: Buloxibutid (C21)
Normalized name: C18-C21 alkane
DrugBank: Buloxibutid (DB18038)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buloxibutid (C21) intra-arterial infusion at doses of 3, 10, 30, 100, and 200 μg/min
Study: 38344891
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (SNP) infusion at doses of 0.8-3.2 μg/min
Study: 38345397
Drug: CB-011 (hypoimmunogenic,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB-011 (hypoimmunogenic, allogeneic anti-BCMA CAR T cell therapy)
Study: 38345463
Drug: Prehydrated collagenated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prehydrated collagenated bone gel (test group; n=10)
Study: 38345529
Drug: Belumosudil oral
Normalized name: belumosudil Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belumosudil oral suspension (200 mg)
Study: 38345529
Drug: Belumosudil oral
Normalized name: belumosudil Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belumosudil oral suspension with food
Study: 38345529
Drug: Belumosudil oral
Normalized name: belumosudil Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belumosudil oral suspension with sweetener/flavor vehicle
Study: 38345529
Drug: Belumosudil oral
Normalized name: belumosudil Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belumosudil oral tablet (reference)
Study: 38345710
Drug: SE-implant (slow-eluting
Approvals — FDA: no, EMA: no, PMDA: no
Description: SE-implant (slow-eluting implant)
Study: 38345710
Drug: FE-implant (fast-eluting
Approvals — FDA: no, EMA: no, PMDA: no
Description: FE-implant (fast-eluting implant)
Study: 38345710
Drug: SE-implant
Normalized name: selenomethionine Se 75
DrugBank: Selenomethionine Se-75 (DB09400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SE-implant
Study: 38345710
Drug: FE-implant
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: FE-implant
Study: 38345718
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy compliance
Study: 38345741
Drug: Optimized medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized medical treatment (OMT)
Study: 38346237
Drug: Plasma exchange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma exchange treatment
Study: 38346307
Drug: Collagenase Injection
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Collagenase Injection
Study: 38347177
Drug: PD-1 inhibitor
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 inhibitor combined with albumin paclitaxel and apatinib
Study: 38347552
Drug: Molecular tumor
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular tumor board (MTB) recommended combination therapy
Study: 38347557
Drug: Routine administrative
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine administrative systems-level data on nursing care outcomes abstracted weekly.
Study: 38347614
Drug: IV iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV iron treatment
Study: 38347736
Drug: Decompressive craniectomy
Normalized name: TUBE DECOMPRESSION BARD #000395
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decompressive craniectomy (DC) plus best medical treatment (BMT)
Study: 38348238
Drug: macitentan 10
Normalized name: macitentan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: macitentan 10 mg, with or without a phosphodiesterase 5 inhibitor (PDE5i)
Study: 38348690
Drug: Zenocutuzumab, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zenocutuzumab, dosage and duration not specified
Study: 38348827
Drug: Social interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Social interventions for support during treatment for endometrial cancer
Study: 38349241
Drug: Real-time fMRI
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real-time fMRI neurofeedback (15 weekly sessions)
Study: 38349241
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) (10 weekly group sessions)
Study: 38349333
Drug: 2 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 × 10^7 HXTCs/m² with VOR 400 mg
Study: 38349371
Drug: Oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin (single-dose treatment twice yearly for 3 years, 6 distributions)
Study: 38349570
Drug: Feladilimab in
Normalized name: Feladilimab
DrugBank: Feladilimab (DB16415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feladilimab in combination with tremelimumab (24/225 mg)
Study: 38349618
Drug: CT‑P41 (60-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT‑P41 (60-mg subcutaneous dose)
Study: 38349618
Drug: US-denosumab (60-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-denosumab (60-mg subcutaneous dose)
Study: 38349712
Drug: Comprehensive Care
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive Care Program (educational videos and follow-up visits by a family medicine physician)
Study: 38349721
Drug: Web-based Culinary
Normalized name: Lens culinaris fruit extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based Culinary Medicine intervention group (CMG) received weekly cooking demonstrations and biweekly nutrition education videos.
Study: 38350047
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy after nephroureterectomy
Study: 38350126
Drug: Subcutaneous catheter
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous catheter change
Study: 38350888
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of systemic therapy with total ablative therapy (TAT) including surgical resection, microwave ablation, and/or stereotactic ablative body radiotherapy (SABR) for at least one lesion.
Study: 38350888
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of systemic therapy without total ablative therapy (TAT).
Study: 38351182
Drug: Nivolumab/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab/radiation therapy
Study: 38351182
Drug: Nivolumab/ipilimumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab/ipilimumab with concurrent radiotherapy
Study: 38351528
Drug: Quality of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality of life assessment using the Functional Assessment of Cancer Therapy
Study: 38352207
Drug: Onion Peel
Normalized name: ONION
DrugBank: Onion (DB10548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onion Peel Extract (OPE) 1,000 mg/day for 8 weeks
Study: 38352524
Drug: Digital anal
Normalized name: Mephitis mephitis anal gland fluid preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital anal rectal examinations (DARE)
Study: 38353018
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for PHCI
Study: 38353107
Drug: Three cycles
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three cycles of neoadjuvant sintilimab + platinum-based chemotherapy
Study: 38353107
Drug: Four cycles
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four cycles of neoadjuvant sintilimab + platinum-based chemotherapy
Study: 38353245
Drug: Integrative medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative medicine program (9-week duration) with recommendations for an anti-inflammatory Mediterranean diet and self-management support
Study: 38353245
Drug: Integrative medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative medicine program
Study: 38354138
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg of frexalimab intravenously every 4 weeks (with an 1800-mg loading dose)
Study: 38354138
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of frexalimab subcutaneously every 2 weeks (with a 600-mg loading dose)
Study: 38354139
Drug: E-cigarettes and
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E-cigarettes and e-liquids, standard-of-care smoking-cessation counseling, optional nicotine-replacement therapy
Study: 38354139
Drug: Standard counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard counseling and a voucher for any purpose (including nicotine-replacement therapy)
Study: 38354140
Drug: Cefepime-taniborbactam (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime-taniborbactam (2.5 g) every 8 hours for 7 days (up to 14 days if bacteremia)
Study: 38354140
Drug: Meropenem (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (1 g) every 8 hours for 7 days (up to 14 days if bacteremia)
Study: 38354688
Drug: Neoadjuvant immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant immunotherapy (PD1/PD-L1 antibody)
Study: 38354904
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein treatment (1.6 g/kg per day)
Study: 38354904
Drug: Usual protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual protein treatment (0.9 g/kg per day)
Study: 38354904
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein treatment in patients with preexisting malnutrition